|Bid||0.0000 x 1400|
|Ask||0.0000 x 1200|
|Day's range||2.7300 - 2.8800|
|52-week range||1.2600 - 6.7500|
|Beta (5Y monthly)||2.41|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.00|
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secur
Shareholders of ASLAN Pharmaceuticals (NASDAQ: ASLN) are primed for a good weekend. Raycroft believes the shares are worth $8 apiece, more than 150% higher than Thursday's closing price. ASLAN, a clinical-stage immunology biotech, only has two treatments in development.
ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.